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Introduction 
Since the global outbreak of COVID-19 that is caused by 
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) in 2020, a lot of aspects of people’s lives are affected 
including their psychological status.1 Neurological 
manifestations of COVID-19 can be divided into those 
affecting the central nervous system (dizziness, ataxia, 
stroke, encephalitis, demyelination) and those affecting 
the peripheral nervous system (anosmia, agnosia, Guillain 
barre syndrome).2,3
It was previously shown that viral diseases affecting the 
respiratory system can cause psychological outcomes that 
may last for a short or long time.1 Follow-up assessment 
of survivors of SARS-Cov-2 infection showed that 
they had multiple psychological disorders including 
depression, panic attacks, obsessive compulsive disorder, 
and post-traumatic stress disorder.4 Their risk of suicide 
and psychosis were significantly higher especially until 
one year of testing positive for SARS.5 Recently, there 
is a focus on the neuropsychiatric presentations of 
COVID-19. It is estimated that more than one-third of 
patients with COVID-19 experience neuropsychiatric 
symptoms, including headache, paresthesia, and disturbed 
consciousness. Neuropsychiatric symptoms usually are 
associated with a more serious form of disease.6 Recent 
studies show that patients affected by COVID-19 may 
show cognitive impairments like delirium. Their mood 
may be also affected by COVID-19 by direct and indirect 
mechanisms and depression, anxiety and insomnia 
may be prevalent in these patients.7 Besides biological 
mechanisms such as positive neurotropism of virus 
immunological and inflammatory responses, the fear of 
dying due to the respiratory infection and social isolation, 
poses a great risk for getting anxiety and panic disorder 
that may impair cognition8,9 In this review we aimed to 
investigated the mechanisms through which COVID-19 
can produce psychological disorders that causes cognitive 
impairment and propose treatment options to decrease 
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the psychological burden and cognitive impairment of 
the disease. 
Delirium 
As little is known about the central nervous system 
(CNS) manifestations of COVID-19, the mechanism 
of delirium in the patients affected by COVID-19 may 
not be fully understood. Taking into consideration the 
severity of illness and ICU admission with the possibility 
of intubation, it is not out of mind that COVID-19 
would cause delirium especially in the older adults 
with underlying conditions and previous cognitive 
impairments.10
Hence delirium in COVID-19 should be considered 
as a primary and secondary cause. In the primary 
hypothesis it is presumed that COVID-19 can target 
the brain directly but in the secondary hypothesis it is 
regarded that the delirium is caused by exacerbating 
the underlying conditions, the electrolytes imbalance 
and ICU admission.11 In a case series of 58 patients 
admitted in the intensive care unit (ICU) because of 
COVID-19 infection, 65% had significant scores in the 
confusion assessment method for the intensive care unit 
(CAM-ICU) and 84% of them had neuropsychiatric 
presentations. Agitation were present in 69% of patients 
which needed additional sedation.12 In a study on the 
discharged patients after 4 weeks, cognitive tests were 
done by telephone. The patients who had delirium during 
admission had significantly lower cognitive scores.13
In a case series that investigated the conditions of 
patients with delirium in COVID-19 units, all the patients 
had an objective or subjective cognitive impairment 
but this report cannot rule out the potential effect of 
COVID-19 neurotropism as an underlying cause of 
delirium.11 Some coronavirus can infect the brain by 
connecting to the medullary cardiorespiratory center and 
induce respiratory failure. By this mechanism coronavirus 
can both cause delirium directly by infecting the brain and 
indirectly by inducing brain hypoxia.14 Another access 
route to the brain is the olfactory bulb. This finding is 
consistent with high rates of anosmia in the patients with 
COVID -19. The virus goes up to the uncinate fasciculus 
and anterior cingulate gyrus.15 Interestingly the dysosmia 
is also common in the patients with Parkinson’s disease, 
Alzheimer’s disease and systemic lupus erythematous 
(SLE).16 In patients with SLE, the severity of anosmia 
correlates with the disease activity.17 The relationship 
between the severity of anosmia and disease severity of 
COVID-19 is not studied that can be a field of research 
for further studies.
It should be considered that inflammation caused by the 
virus can also exacerbate the delirium in affected patients. 
Patients critically affected by COVID-19 who need ICU 
care, are at an impending risk of advanced delirium which 
can be aggravated with using sedatives and previous 
medical comorbidities especially in the elderly.18
Encephalitis
A case series from Wuhan illustrated that at least 20% of 
patients who survived COVID-19 infection experienced 
encephalopathy.19  A Chinese case report showed that 
about 20% of the patients that died from COVID infection, 
had findings in favor of encephalopathy.20
Another case report has been published that shows a 
possible correlation between COVID-19 infection and 
an acute hemorrhagic necrotizing encephalopathy in a 
44-year-old woman that can be due to cytokine storm 
after COVID infection.19 A possible way of predicting 
the virus complication is by comparing it to the HIV 
virus. HIV virus causes olfactory bulb damage and causes 
significant encephalopathy. In patients affected by HIV 
the reduced amount of olfactory function is correlated 
with their cognitive dysfunctions.4,21,22 This matter may 
be also present in COVID-19 disease that needs further 
investigation. In patients with confessional state that 
were compatible with neuropsychiatric presentation 
of COVID-19, magnetic resonance imaging showed 
enhanced leptomeningeal and hyper perfusion in the area 
of frontal and temporal lobes.12 Electroencephalogram 
evaluation did not show any specific pattern except 
diffuse slowing in the background that was compatible 
with encephalopathy.12
Anxiety
Simultaneous with COVID-19 pandemic, we have 
pandemic of fear of getting COVID-19 which is related to 
the abrupt change of people’s life conditions.23 The anxiety 
caused by fear of dying can impair the cognitive functions 
such as memory, attention, learning, decision making, 
similar to other stressors.24,25 In a study conducted in 
the US and Canada, people who had previous anxiety 
disorders were more prone to the stress caused by 
COVID-19 pandemic.26 The COVID-19 lockdown as well 
as the pandemic, increased depression and anxiety among 
individuals. In a study on 5545 random people in Spain, 
65% reported depression and anxiety symptoms during the 
COVID-19 pandemic. They measured these symptoms by 
validated questionnaires (General anxiety disorder 7-item 
questionnaire, patient health questionnaire 9) (GAD-7, 
PHQ-9). After an intervention on their lifestyle including 
the prohibition of bad news and promoting their diet to a 
healthy and balanced one, they were able to significantly 
reduce depression and anxiety symptoms; however, it 
should be mentioned that the study was cross-sectional 
and did not show causality.27 
In a study on 114 patients with positive COVID-19 test, 
PHQ-2 and GAD-2 questionnaires were used to assess 
depression and anxiety, respectively. Among COVID-19 
presentations, only anosmia and agnosia were correlated 
with depression and anxiety symptoms. This matter 
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can be explained in two ways. Dysfunction in chemo-
sensation had been shown to be correlated with anxiety, 
depression and less satisfaction of life. On the other 
hand, as COVID-19 can directly invade and damage the 
olfactory bulb, this positive correlation may prompt a 
hypothesis that depressed mood and anxiety may also be 
a result of direct invasion of the virus.28
Stroke
In a study on 174 patients with acute stroke and positive 
COVID-19 test, the National Institutes of Health Stroke 
Scale was 10 vs 6 in the control group, and their mortality 
rate and disability rate were 26.7% and 51%, respectively.29 
In another study, Cognitive function was examined in 
227 patients three months after admission to hospital 
for ischemic stroke, and in 240 stroke-free controls, 
using 17 scored items that assessed memory, orientation, 
verbal skills, visuospatial ability, abstract reasoning, and 
attentional skills.30 Cognitive impairment, defined as 
failure on any four or more items, occurred in 35.2% of 
patients with stroke and in 3.8% of the controls. Among 
patients with stroke, cognitive impairment was most 
frequently associated with major cortical syndromes and 
with infarctions in the left anterior and posterior cerebral 
artery territories.30
In a study on 645 subjects, 38% of patients had 
cognitive impairment in the three-month follow-up. 
Cognitive impairment was associated with age older 
than 75, left hemispheric strokes, visual field defects, 
and degree of disability.31 In a study on 170 patients 
with stroke or transient ischemic attack, the cognitive 
dysfunction was associated with white matter lesions not 
the volume and number of lesions.32 This matter should 
be considered in justifying stroke lesions in the patients 
with stoke and COVID-19. In a four-year follow-up study 
of patients with acute stroke, 84% of patients had severe 
cognitive dysfunction in favor of post-stroke dementia 
(Montreal Cognitive Assessment: 20±4.7). this indicates 
an important indication for cognitive assessment and 
rehabilitation for patients with acute stroke.33
Hypoxia
Another potential cause of cognitive dysfunction in 
patients affected by COVID-19 is hypoxia. We have 
inferred from previous research on sleep apnea that 
hypoxia induces cognitive impairments.34 Since hypoxia 
can be related to and caused by acute respiratory distress 
syndrome (ARDS) or pulmonary embolism35 in these 
patients, COVID-19 can cause hypoxia through various 
pathways. It can also suppress the central respiratory 
system in the medulla.14 Interventions for improving 
hypoxia can be positioning the patients in the prone 
position and using thrombolysis with tissue plasminogen 
activator.36 ARDS results in hypoxemia and uremia 
which leads to platelet dysfunction, epithelial damage, 
disseminated intravascular coagulation and presumed 
elevated risk of cerebrovascular accident.37
Cognitive Impairments in COVID-19
Sometimes, neurological symptoms can be a part of 
COVID-19 symptoms. In a study 36% of 39 patients had 
impairments in the executive function that can explain 
the prevalence of attention impairments and confusion in 
the reported articles which suggests a dysfunction in the 
frontal lobe area.38,39 Elder patients, especially those with 
medical comorbidities, have a higher risk of developing 
psychiatric symptoms after COVID infection. They have 
even a higher risk of mood disturbance after recovering 
from the infection and hospital discharge. Some of 
them reported anxiety, depressed mood, post-traumatic 
stress disorder, and increased cognitive impairments. 
In a prospective study in the United Kingdom on 
431 051 patients with different risk factors for getting 
COVID-19 infection, after controlling the social risk 
factor, only patients with higher cognitive impairments 
had higher risk of SARS-Cov-2 infection.40 In the terms 
of classifying the domains of cognitive dysfunction, a 
retrospective study in the united states indicated that 
24% of 50 patients had impairments in the short-term 
memory.41 In a study on patients with acute and subacute 
COVID-19 infection that had neurological symptoms, 
the prevalence of neuroimaging characteristics were 
investigated. About a third of patients had diffuse hyper/
hypo densities that were compatible with leukoaraiosis 
and leukoencephalopathy.42
As a result of quarantine, social isolation, impairs 
cognition  through decreasing social interaction, 
cognitive training programs and results in increased 
feeling of loneliness that especially deteriorates the 
cognitive functions in the elderly with dementia.43 In the 
elder patients hospitalized for COVID-19 infection, the 
most prevalent neurological syndrome was altered level 
of consciousness44 and also they may present with some 
aberrant symptoms such as loss of appetite, confusional 
state, sudden onset of disorientation and psychological 
distress which may lead to denial of receiving proper 
treatment.45 In a recent study conducted in Spain in 2020, 
among the patients with positive COVID-19 test, 10 
patients had psychotic features with no previous history 
of psychiatric problem. Some of them even developed 
psychosis as auditory hallucination and delusion. In 
the psychological tests they had attention deficit but 
fortunately the symptoms resolved after 2 weeks of 
onset. These transient episodes of psychosis can be due 
to systemic inflammation and side effects of COVID-19 
treatment as well as ICU care.46 Cognitive impairment 
can also be a side effect of treatments for COVID-19, as 
shown in a study in four patients COVID-19 requiring 
ICU admission. The patients developed impairments in 
memory and functions of  frontal lobe which exacerbated 
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with treatment with immunoglobulin after five days.47
Role of Inflammation in Cognitive impairment of 
COVID-19 
Recently published studies have shown a systemic 
inflammation called “cytokine storm”. As COVID-19 
can cause pro-inflammatory cytokines release i.e. tumor 
necrosis factor and inteleukine-6, blood brain barrier will 
be disrupted and glial and neural cells of the brain can be 
damaged resulting in neurocognitive symptoms.48,49
There is also evidence of inflammation in 
neurodegenerative processes similar to Alzheimer’s 
disease which shows the shared pathological mechanism 
in COVID-19 in which cognitive impairments are 
associated with neurodegenerative diseases.50 In animal 
studies it is shown that the hippocampus is susceptible 
for viral infections resulting in memory deficit especially 
in the spatial memory domain.51,52 Considering these 
studies, it is presumed that COVID-19 can cause cognitive 
impairments by inducing systemic inflammation. 
Proposed Treatments of Cognitive Impairment in 
COVID-19
In the managing of patients with presumed cognitive 
dysfunction because of hypoxia, it is important to 
position the patient in the prone position and consider 
using thrombolysis if embolic source is suspected. In the 
patients with agitation that are cooperative in using pills, 
second generation of antipsychotics like aripiprazole, 
quetiapine and olanzapine is preferred. But in the patients 
that refuse to take medications, chlorpromazine can be 
effective. There is also a study that indicates a promising 
role of haloperidol by effecting the sigma receptor to treat 
SARS-CoV2.53 Dexmedetomidine and clonidine patches 
can also be used to decrease anxiety in patients admitted 
to the ICU. Benzodiazepine are not usually preferred 
because of the increased risk of sedation and respiratory 
failure.11 As we have significant cognitive impairments in 
patients infected by COVID-19, cognitive rehabilitation 
therapy has an important role to improve their function 
and escalate the independence.54
Cognitive rehabilitation therapy can also reduce the 
effect of cognitive impairments in the patient’s daily 
life.55 Recent studies showed that some computer-based 
cognitive rehabilitation programs in form of brain 
exercise games can have an improving effect.56 The 
role of cognitive behavioral treatments in reducing the 
detrimental effect of anxiety should be considered.57
Conclusion
Among patients affected by COVID-19, there are different 



























Figure 1. COVID -19 can cause direct invasion to CNS that causes inflammation and encephalitis. Inflammation can cause delirium, 
epithelial dysfunction and CVA and also causes chronic fatigue syndrome which is correlated with cognitive impairments. COVID-19 
can require quarantine which increases anxiety that impairs cognition. COVID-19 also involves the lungs and induces hypoxia which 
deteriorates brain functions. The proposed treatments for cognitive impairment in the patients with COVID-19 infection, second generation 
antipsychotics, cognitive rehabilitation therapy and cognitive behavioral therapy is proposed. 
CNS: Central nervous system, CVA: Cerebrovascular accident, CRT: Cognitive rehabilitation therapy, CBT: Cognitive behavioral therapy. 
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1). COVID-19 can affect the CNS directly by invasion 
and indirectly by inducing hypoxia, inflammation and 
delirium. The pandemic and fear of infection can also 
cause anxiety which impairs the cognition as well. By 
assessing the patients’ cognition and knowing the higher 
probable cause of cognitive impairment, we can form a 
better strategy to better treat the impairment. Cognitive 
behavioral treatment can be effective in reducing the 
anxiety and cognitive rehabilitation therapy can be used 
to lower the detrimental effects of cognitive impairment 
caused by COVID-19.
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